92 results on '"Halfvarson, Jonas"'
Search Results
2. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
3. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition
4. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden
5. Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies
6. 150: BIOMARKERS FOR IBD USING OLINK PROTEOMICS INFLAMMATION PANEL: PRELIMINARY RESULTS FROM THE COLLIBRI CONSORTIUM
7. Tu1545: TRANS-CONTINENTAL ANALYSIS OF OVER 2,000 INFLAMMATORY BOWEL DISEASE PATIENTS IMPLICATES GEOGRAPHY, DISEASE TYPE, AND EXPOSURE TO IMMUNOSUPPRESSION AS DRIVERS OF SARS-COV-2 SEROPREVALENCE
8. Sa1583: SERUM PROTEOMIC MARKERS THAT PREDICT FUTURE CROHN'S DISEASE DEVELOPMENT ARE ASSOCIATED WITH GUT BARRIER FUNCTION, SUBCLINICAL GUT INFLAMMATION AND IMMUNE RESPONSE TO BACTERIAL ANTIGENS
9. Tu1855 LONG-TERM RISK OF HEART FAILURE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION-BASED, SIBLING-CONTROLLED COHORT STUDY
10. A Pyrosequencing Study in Twins Shows That Gastrointestinal Microbial Profiles Vary With Inflammatory Bowel Disease Phenotypes
11. Challenges and Opportunities in IBD Clinical Trial Design
12. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
13. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD
14. Mo1775 INFLAMMATORY BOWEL DISEASE AND RISK OF COLORECTAL POLYPS: A NATIONWIDE POPULATION-BASED COHORT STUDY FROM SWEDEN
15. Mo1768 LONG-TERM RISK OF STROKE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED, SIBLING-CONTROLLED COHORT STUDY 1965-2019
16. Su1759 IDENTIFICATION AND VALIDATION OF A LIPIDOMIC SIGNATURE AS A NOVEL DIAGNOSTIC BIOMARKER OF PEDIATRIC INFLAMMATORY BOWEL DISEASE
17. Su1757 A NOVEL DIAGNOSTIC SERUM PROTEIN SIGNATURE FOR PEDIATRIC INFLAMMATORY BOWEL DISEASE: A DISCOVERY AND VALIDATION STUDY IN TWO INDEPENDENT INCEPTION COHORTS
18. Su1758 A NOVEL SERUM PROTEIN SIGNATURE AS BIOMARKER FOR INFLAMMATORY BOWEL DISEASE: A DIAGNOSTIC PERFORMANCE AND PREDICTION MODELLING STUDY USING DATA FROM TWO INDEPENDENT INCEPTION COHORTS
19. Sa1818 LONG-TERM RISK OF ARRHYTHMIAS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED, SIBLINGCONTROLED COHORT STUDY 1965-2019
20. Sa1771 ATHEROSCLEROSIS AS A RISK FACTOR FOR IBD; A POPULATION-BASED CASE-CONTROL STUDY
21. 690 STATIN USE AND RISK OF COLORECTAL CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
22. Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor ACE2 and TMPRSS2 in Inflammatory Bowel Disease
23. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease
24. Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting
25. 398 THE GEM PROJECT: IDENTIFICATION OF A SERUM PROTEOMIC SIGNATURE ASSOCIATED WITH RISK OF FUTURE CROHN'S DISEASE ONSET IN A COHORT OF HEALTHY AT-RISK INDIVIDUALS
26. Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY
27. Mo1886 REAL-WORLD EFFECTIVENESS OF VEDOLIZUMAB IN CROHN'S DISEASE: WEEK 52 RESULTS FROM THE SWEDISH MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL SVEAH CD STUDY
28. Mo1115 WHOLE-BLOOD EXPRESSION PROFILES IN INFLAMMATORY BOWEL DISEASE REVEAL TRANSCRIPTION FACTOR INVOLVEMENT
29. 762 INCREASED RISK OF SMALL BOWEL CANCER AND SMALL BOWEL CANCER DEATH IN INFLAMMATORY BOWEL DISEASE: A BINATIONAL POPULATION-BASED STUDY
30. Mo1764 – Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease
31. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm
32. Tu1828 - Fecal Microbiota in Treatment-Naive Ulcerative Colitis and its Relation to Treatment Escalation
33. Mo1894 - Clinical Effectiveness of Vedolizumab: Interim Analysis of the Swedish Observational Study on Vedolizumab Assessing Effectiveness and Healthcare Resource Utilization in Patients with Ulcerative Colitis (Sveah UC)
34. Mo1915 - The Impact of Thiopurines on the Natural History and Surgical Outcome of Ulcerative Colitis: A Cohort Study
35. 15 - Health Care Use, Work Loss, and Total Costs in Incident and Prevelant Ulcerative Colitis: Results from a Nationwide Study in Sweden
36. Mo1892 - Clinical Effectiveness of Vedolizumab: Interim Analysis of the Swedish Observational Study on Vedolizumab Assessing Effectiveness and Healthcare Resource Utilization in Patients with Crohn's Disease (Sveah CD)
37. Epigenetic Alterations at Diagnosis Predict Susceptibility, Prognosis and Treatment Escalation in Inflammatory Bowel Disease and IBD Character
38. Su1784 PEA Immunoassay Technology Identifies Novel Serum Biomarkers That Can Diagnose and Classify Inflammatory Bowel Diseases: IBD Character Consortium
39. Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel
40. Tu1368 Vedolizumab in Inflammatory Bowel Disease, the First Experience From the Swedish IBD Registry (SWIBREG)
41. Mo1802 Intestinal Dysbiosis in Collagenous Colitis
42. Su1201 Proximity Extension Assay Technology Identifies Novel Serum Biomarkers for Predicting Inflammatory Bowel Disease: IBD Character Consortium
43. Su1316 Unchanged Surgery and Hospitalization Rates in an East-West European Inception Cohort Despite Differences in Use of Biologicals - 3-Year Follow-Up of the ECCO-EpiCom Cohort
44. Su1945 - Proximity Extension Assay based Proteins Show Immune Cell Specificity and can Diagnose and Predict Outcomes in Inflammatory Bowel Diseases: IBD Character Study
45. Su1827 - Epigenetic Alterations at Diagnosis Predict Susceptibility, Prognosis and Treatment Escalation in Inflammatory Bowel Disease and IBD Character
46. Sa1114 The Cost of Medical Management, Surgery and Clinical Investigations in a European Population-Based Inception Cohort From the Biological Era – An ECCO-Epicom Study
47. 6 Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants
48. 1003 Association of Protective IL13 Polymorphism With Irritable Bowel Syndrome
49. Tu1933 Influence of Genetics in the Expression of Serological Markers in Twins With IBD
50. Mo1004 Is There an East-West Gradient in the Incidence of IBD in Europe? and Further Far East in China? First Results From the Epicom Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.